Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 62%
Buy 31%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is well-positioned in the ophthalmic industry with its unique focus on developing novel treatments for glaucoma, corneal disorders, and retinal diseases. The company's iDose TR implant, which provides extended delivery of glaucoma medication, has shown strong momentum in adoption and has the potential to generate significant revenue in 2027. Despite potential headwinds from LCDs, Glaukos has a strong pipeline of products, including its sustained release iDose TR travoprost implant and its emerging Epioxa treatment for keratoconus. The company also has a solid financial position and potential growth opportunities from its patient assistance program and referral network. However, key risks include potential challenges with sales execution, increased competition in the MIGS market, and reimbursement challenges.

Bears say

Glaukos is facing several challenges in the marketplace due to upcoming changes in LCD criteria and restrictions on its iDose product. These changes could significantly impact the company's revenue, potentially causing a -10% or $30M decrease in iDose sales in CY27. Additionally, the company's iDose product may face headwinds due to restrictions on combination use with other MIGS procedures. Furthermore, the company's profitability may be affected as investments are made in its pipeline, and the performance of its recently launched product, Epioxa, has been limited thus far with only one doctor completing a single case.

Glaukos (GKOS) has been analyzed by 13 analysts, with a consensus rating of Buy. 62% of analysts recommend a Strong Buy, 31% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 13 analysts, Glaukos (GKOS) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $179.54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $179.54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.